Pharma Mar S.A. Logo

Pharma Mar S.A.

PHM | MC

Overview

Corporate Details

ISIN(s):
ES0169501022 (+1 more)
LEI:
959800QWKZ45ZQC2AV58
Country:
Spain
Address:
Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharma Mar S.A. is an integrated biopharmaceutical company focused on the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to create novel therapies, with a particular focus on rare cancers. PharmaMar manages the entire drug development process, from research, supported by its extensive collection of over 500,000 marine invertebrate samples, to marketing. Its portfolio of approved anti-tumor drugs includes Yondelis® (trabectedin) for soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pharma Mar S.A.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-19 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-18 00:00
Post-Annual General Meeting Information
Se informa que todas las propuestas de acuerdos presentadas por el Consejo a la…
Spanish 389.6 KB
2025-06-18 00:00
Investor Presentation
Se remite copia de la presentación a accionistas que será realizada en la Junta…
Spanish 2.5 MB
2025-06-09 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-09 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-05 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-26 17:41
Transaction in Own Shares
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 171.3 KB
2025-05-23 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-22 00:00
Director's Dealing
Motivo de la notificación: Persona Estrechamente Vinculada
Spanish 91.4 KB
2025-05-21 08:27
Regulatory News Service
La Sociedad presenta la solicitud en la UE para comercializar lurbinectedina en…
Spanish 744.9 KB
2025-05-19 17:40
Transaction in Own Shares
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 183.1 KB
2025-05-19 08:26
Regulatory News Service
La Sociedad anuncia que su socio Adium Pharma S.A. ha recibido la aprobación pa…
Spanish 751.5 KB
2025-05-13 00:00
Director's Dealing
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-12 17:38
Transaction in Own Shares
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 165.2 KB
2025-05-06 11:42
Pre-Annual General Meeting Information
La Sociedad remite anuncio de convocatoria de la Junta General Ordinaria de Acc…
Spanish 495.5 KB

Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK